Drug Trial Radar · NCT07029412
Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)
Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Aug 26, 2025
Primary completion
Apr 18, 2026
Study completion May 1, 2026
Sponsor
- Lead sponsor
- MBX BiosciencesIndustry
- Sponsor type
- Industry
- First posted
- Jun 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the preliminary efficacy of single SC administration of MBX 1416 at different dose levels in patients with PBH
Conditions
- Postbariatric Hypoglycemia
Interventions
MBX 1416 (INN imapextide)Drug
A single subcutaneous injection of MBX 1416 at a low dose and a high dose approximately 2 weeks apart.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes from baseline to post-treatment in glucose nadir during a standardized MMTT following different dose levels of MBX 1416.Time frame: The duration of the study will be approximately 67 days from screening to end of study (EoS) for any given participant
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
MBX Biosciences Investigational Site
Aurora, Colorado
MBX Biosciences Investigational Site
Morehead City, North Carolina
MBX Biosciences Investigational Site
Knoxville, Tennessee
MBX Biosciences Investigational Site
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.